Detalles de la búsqueda
1.
Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study.
J Eur Acad Dermatol Venereol
; 28(6): 790-8, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23679896
2.
Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study.
Br J Dermatol
; 167(3): 658-67, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22564148
3.
Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.
Br J Dermatol
; 167(6): 1374-81, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22897348
4.
Economic burden of comorbidities in patients with psoriasis is substantial.
J Eur Acad Dermatol Venereol
; 25(2): 157-63, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-20561129
5.
Systematic review: the costs of ulcerative colitis in Western countries.
Aliment Pharmacol Ther
; 31(7): 693-707, 2010 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-20064142
6.
Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease.
Aliment Pharmacol Ther
; 31(12): 1296-309, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20298496
7.
The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy.
Aliment Pharmacol Ther
; 32(10): 1228-39, 2010 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-20955442
Resultados
1 -
7
de 7
1
Próxima >
>>